‘Gamida Cell’ Closes $10M For Stem Cell Treatment

Israeli company Gamida Cell announced today that it has closed an internal financing round of $10 million from all major shareholders. According to the company, the financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx. The product is in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma who can be cured by bone marrow transplantation but do not have a matched bone marrow donor.